Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	96.49	22.47	46.35	64.07	126.26	36.11
Short-Term Investments	259.1	147.56	92.01	22.68	26.01	235.55
Cash & Cash Equivalents	355.6	170.03	138.36	86.74	152.28	271.66
Cash Growth	235.67%	22.89%	59.50%	-43.04%	-43.95%	69.73%
Receivables	1.53	1.01	0.03	0.01	0.4	56.53
Inventory	0.51	0.38	0	0	0	4.24
Other Current Assets	7.01	5.13	2.48	2.16	5.05	5.32
Total Current Assets	364.65	176.55	140.87	88.92	157.72	337.75
Property, Plant & Equipment	7.2	7.51	8.48	3.45	0.3	14.05
Goodwill and Intangibles	44.54	44.54	44.54	44.54	44.54	64.26
Other Long-Term Assets	0.83	0.83	0.41	0	1.23	1.66
Total Long-Term Assets	52.57	52.88	53.43	47.99	46.07	79.96
Total Assets	417.22	229.43	194.3	136.91	203.79	417.72
Accounts Payable	8.07	14.39	10.4	9.15	5.47	12.18
Current Debt	0	0	0	0	11.65	11.01
Other Current Liabilities	15.33	17.16	12.78	12.97	29.69	42.15
Total Current Liabilities	23.4	31.55	23.17	22.12	46.81	65.34
Long-Term Debt	104.95	104.77	54	1.19	0	234.17
Other Long-Term Liabilities	0	0	0	0	0.61	1.1
Total Long-Term Liabilities	104.95	104.77	54	1.19	0.61	235.27
Total Liabilities	128.35	136.32	77.18	23.31	47.42	300.61
Total Debt	104.95	104.77	54	1.19	11.65	245.18
Debt Growth	93.29%	94.01%	4438.07%	-89.78%	-95.25%	0.07%
Retained Earnings	-1,815.24	-1,766.84	-1,589.72	-1,487.78	-1,400.02	-1,341.44
Comprehensive Income	-0.05	0.03	-0.43	-0.01	-0.01	0.08
Shareholders' Equity	288.87	93.11	117.12	113.6	156.37	117.1
Net Cash / Debt	250.65	65.25	84.35	85.55	140.63	26.48
Net Cash / Debt Growth	385.39%	-22.64%	-1.40%	-39.16%	431.16%	-
Net Cash Per Share	1.02	0.30	0.51	0.59	1.27	0.23
Working Capital	341.25	145	117.69	66.8	110.91	272.41
Book Value Per Share	1.18	0.42	0.71	0.78	1.41	1.10

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).